LQDA

Liquidia Corporation

Fundamental data last updated:October 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

 


Analyze LQDA on TradingView

VALUATION

P/E

244.74

Market Cap ($M USD)

$5.52B

Forward P/E

8.19

PEG

0.00

PRICE TO SALES

19.15

PRICE TO BOOK

50.28

EV / EBITDA

105.30

5-Year Average P/E

Free Cash Flow Yield

0.75%

DCF Value

$-101.69

Graham Number

$2.65

Price to FCF

134.06

EV to FCF

133.14

Earnings Yield

0.41%

FCF Yield

0.75%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.25

Next Year EPS Growth Estimate

$7.57

Next Year Revenue Growth Estimate

$1.66B

Return on Equity (ROE)

46.82%

FREE CASH FLOW

Operating Margin

15.81%

Debt-to-Equity

4.42

Piotroski F-Score

6

Altman Z-Score

11.14

Return on Invested Capital (ROIC)

18.09%

Current Ratio

2.22

Quick Ratio

2.03

Net Debt to EBITDA

-0.73

Interest Coverage

1.75

Gross Profit margin

91.78%

FCF PER SHARE

$0.47

REVENUE PER SHARE

$3.27

Analyze LQDA on TradingView

Gainseekers Quantitative Analysis

Summary

The market has priced Liquidia Corporation with a Forward P/E of 5.39, suggesting optimism about future earnings despite its current negative earnings yield. However, the stark contrast between its snapshot price and the deeply negative DCF Value indicates potential overvaluation. The Altman Z-score of 5.44 suggests financial stability, yet the negative ROIC and operating margin highlight inefficiencies in capital deployment. The market seems to be betting on a turnaround, but the current fundamentals paint a picture of risk rather than reward.

AI Exposure / Tech Reliance

In the biotechnology sector, Liquidia is well-positioned to leverage AI for drug discovery and personalized medicine, enhancing its R&D efficiency. The industry's rapid adoption of tech innovations could bolster Liquidia's competitive edge. However, the pace of tech integration will be crucial for maintaining relevance.

The Bull Case

For GARP investors, Liquidia's Forward PEG ratio of 0.0049 is a beacon of potential undervaluation, indicating significant growth prospects relative to price. Despite a low Piotroski F-Score of 3, the company's robust gross profit margin of 97.21% suggests strong pricing power. The Altman Z-score further reassures investors of its financial health, making it an intriguing play for those betting on a biotech resurgence.

The Bear Case

The glaring negatives cannot be ignored. A Price/Book ratio of 82.51 and Price/Sales of 23.59 signal extreme overvaluation, especially when coupled with a negative FCF Yield. The stock's proximity to its 52-week high raises concerns about technical overextension. With a Return on Equity of -209.33% and negative earnings, the structural risks are pronounced, casting doubt on its ability to generate sustainable profits.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$63.00

Institutional Ownership %

1-Year Beta

0.42

Insider Buying % (6 Mo)

Distance to 52-Week High

2.31%

Distance to 52-Week Low

80.90%

EARNINGS SURPRISE %

52.94%

50-DAY SMA

$43.58

200-DAY SMA

$34.06

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.